

Sample ID: **ACTN01029999T** | Gender: **Male** | Birth year: **1950**

Tumor: **Skin - Melanoma**

Summary

Patient clinical history (19-Oct-2021)

Relevant systemic treatment history	Vemurafenib (2020), Ipilimumab (2021)
Other oncological history	Resection (2019)
	Previous primary tumor: Bone/Soft tissue Schwannoma (2018, considered active)
Relevant non-oncological history	Pancreatitis, Myocardial infarction

Patient current details (19-Oct-2021)

WHO status	1
Unresolved toxicities grade => 2	Fatigue (2), Dizziness
Significant infection	No
Significant aberration on latest ECG	Atrial arrhythmia
Cancer-related complications	Ascites

Tumor details (19-Oct-2021)

Stage	IV
Biopsy location	Liver
Lesions in CNS / Brain / Bone / Liver	Yes (active, not symptomatic) / No / Unknown / Yes
Other lesions	Pulmonal, Abdominal
Measurable disease (RECIST)	Yes

Laboratory (19-Oct-2021)

Liver function	Total bilirubin		
	ASAT	(< 33 U/l)	36 U/l (no trend information available)
	ALAT		
	ALP		
	Albumin		
Kidney function	Creatinine		
	CKD-EPI eGFR	(> 100 mL/min)	> 100 mL/min (29-Sep-2021)
Other	Hemoglobin	(6.5 - 9.5 mmol/L)	5.5 mmol/L (no trend information available)
	Thrombocytes	(155 - 350 10 ⁹ /L)	150 10⁹/L (out of range for 2 cons. measurements, trend down)

Molecular results

Molecular results have reliable quality	Yes
Actionable molecular events	BRAF V600E

Conclusion

Coming soon

Treatment Options

Coming soon